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Summary
Background: Injecting drug use (IDU) is a major driver of the European hepatitis C virus (HCV) epidemic. National 
data on prevalence of HCV amongst Irish drug users remains confined to certain treatment sites and prison settings. Aim: 
To examine the prevalence of HCV infection and risk factors associated with infection among the 228 patients attending 
agonist opioid treatment (AOT) in a clinic in Dublin. Methods: A retrospective cross-sectional study was conducted us-
ing data collected from Health Research Board (HRB) forms and standardised written and electronic assessment forms 
routinely completed on treatment initiation. Results: The prevalence of HCV infection was 63.6 % (n= 145) with no sig-
nificant gender difference (p=0.717). Patients who were infected with HCV were older than those uninfected (41.1 ± 7.5 
years versus 37.5 ± 8.5 years; p = 0.001), with prevalence significantly lower in younger adults (p=0.002). Multivariate 
analysis identified age of first drug use (p=0.002) and first injection (p=0.001), type of first drug used; cannabis (p=0.015), 
heroin (p=0.014) and cocaine (p=0.018) and early age of AOT entry (p=0.001) as the most significant risk factors for HCV 
infection in this cohort. Those with no IDU had decreased odds of being HCV positive by 91.1%. Conclusion: Data for 
this Irish sample indicates high prevalence of HCV infection, and the need to consider age of first drug onset and injecting 
use, particular drug types and earlier commencement of AOT to inform targeted HCV treatment and prevention interven-
tions in Ireland. 
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1. Introduction
Worldwide one hundred and eighty five million 
people are estimated to have acquired the hepatitis 
C virus (HCV) [38]. In the World Health Organiza-
tion (WHO) European Region, fifteen million adults 
are estimated to have active HCV infection as de-
fined by the presence of HCV-RNA [22, 28]. HCV 
antibody prevalence levels in the European general 
population range from 0.1% to 22%, with prevalence 
lower in northwestern European countries and high-
er in the countries of the south and southeast [19]. 
This translates into a regional adult prevalence rate 
of 2.0% [22]. Chronic disease outcomes occur in 55-
85% of untreated HCV cases, with long term and 
chronic consequences including liver cirrhosis, liver 
failure and hepatocellular carcinoma. HCV is associ-
ated with impaired quality of life [51], with rates of 
advanced liver disease, related healthcare costs, and 
liver related mortality and morbidity rising [20]. 
HCV epidemics are driven by transmission in 
the smoking or inhaling of heroin, cocaine or crack 
[43], injecting of drugs [14, 50, 52] and from hetero-
sexual and homo-sexual contact [49]. Injecting drug 
use (IDU) is a major driver of the European HCV 
epidemic [28]. HCV is primarily transmitted through 
unsafe injection practices, including sharing of nee-
dles, cookers, cottons, rinse water, and the practice of 
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backloading [42]. 2010/11 data across 18 European 
countries has indicated that IDU accounts for 58% 
of HCV diagnosis [10]. Two million of the WHO 
European Region’s 15 million adults with HCV-RNA 
are people who inject drugs (PWID) [22]. Hahne 
et al. [19] in their systematic review estimate HCV 
antibody prevalence among PWID in 29 European 
countries ranging from 5% to 90%. In eight of the 
12 countries with HCV antibody data in the 2013 
European Drug Report, prevalence exceeded 40% 
in national samples of PWID. Recent increases in 
HCV infection rates in PWID are observed in some 
European countries, despite enhanced coverage of ef-
fective prevention strategies [29]. Elsewhere, median 
prevalence among PWID in the United States (US) is 
estimated to be 65% [17, 39].
Continued risk of new HCV outbreaks and clus-
ters are evident globally. In recent years, clusters of 
acute HCV infection amongst those misusing pre-
scription opioids and transitioning to IDU are report-
ed in the United States [25]. Outbreaks amongst other 
at risk populations include new injectors originating 
from the prescription opioid epidemic [5]; men who 
have sex with men (MSM) particularly among those 
infected with HIV [18], and injectors of new synthet-
ic psycho-actives [13]. Difficulties also centre on high 
prevalence of HCV in an aging PWID population, 
with many undiagnosed and not accessing HCV pre-
vention, care and treatment [14] and with low HCV 
treatment uptake reported among PWID in many 
settings [23, 28, 52]. PWID whilst being at greatest 
risk of HCV viral infection, are often denied immedi-
ate treatment due to concerns around on-going risk 
behaviour [50]. HCV treatment outcomes in PWID 
however are comparable to patients with no history 
of drug use [3]. Treatment also eliminates potential 
for further transmission [35]. The advocated ‘HCV 
cascade of care’ consists of enhanced diagnosis, link-
ing of individuals into HCV care, increasing treat-
ment uptake and enhancing viral cure, and requires 
an integrated evaluation model addressing multiple 
points along the cascade [30]. Combined harm reduc-
tion, agonist opioid treatment (AOT) and needle and 
syringe exchange programmes (NSP) and provision 
of AOT alone can reduce HCV incidence [15]. The 
continued development of HCV treatment has created 
opportunities to offer HCV treatment in conjunction 
with addiction treatment in a holistic manner, particu-
larly to the aging patient with history of IDU [36]. 
In Ireland, up until 2004, HCV was not a notifi-
able disease, although cases could be notified as ‘viral 
hepatitis type unspecified’ [7]. The National Hepatitis 
C Strategy in 2011-2014 observes the limited infor-
mation available on distribution of HCV infection, 
and outlines a series of action plans to reduce HCV 
transmission and improve patient care in Ireland. Lit-
tle has been published in Ireland on the prevalence 
of co-infection of HCV with HIV and/or hepatitis B 
[33]. More than 10 000 people were HCV infected in 
1989–2004, with the numbers peaking in 2000 [4]. 
There were 9, 282 cases of HCV notified in Ireland 
between 2004 and 2010 (surveillance data has been 
implemented since 2007). It is estimated now that 
between 20 000-50 000 people in Ireland are chroni-
cally infected with HCV (prevalence of 0.5–1.2%), 
and is similar to other Northern European coun-
tries. Of the six HCV genotypes, Genotype 1 and 3 
are most common in Ireland [6, 26]. Risk factors for 
HCV status in Ireland are similar to extant literature 
elsewhere and centre on injecting drug use, length of 
time injecting, frequency of injecting, needle shar-
ing and having a prison history [1, 4, 44, 48]. It is 
estimated that 70% of patients in drug treatment are 
HCV infected [33]. Most recent data indicates preva-
lence of HCV in the Irish PWID population ranges 
from 62%-81% [21]. Localised prevalence estimates 
within the PWID population attending community 
drug services range from 54% [45] to 84% [44]. Irish 
prison inmates and entrants are 81% [1] and 72% 
[31] respectively. Smyth et al. [47] in a later study 
reported on incidence of HCV among PWID attend-
ing treatment in Dublin was 66 per 100 person years. 
Grogan et al. [16] reported an incidence of 24.5 per 
100 person years among a sample (n=358) of Irish 
opiate users (including some non-injectors) attending 
treatment. Recent studies in Irish prisons of patients 
on methadone indicated the need for more extensive 
screening of HCV and other blood borne virus infec-
tions [9, 12]. Addiction services in Ireland provide 
routine screening for HCV infection with follow-up 
PCR testing and referral to the acute hospital special-
ist services when recommended [7]. However, low 
uptake of screening and follow up assessments are 
reported amongst Irish drug users [37, 40] and pris-
oners [32]. Other concerns centre on continued HCV 
risk behaviours amongst Irish drug users despite pres-
ence of harm reduction interventions [46]. The aims 
of the study were primarily to estimate the preva-
lence of HCV infection among patients attending the 
Thompson Centre, a drug treatment clinic providing 
AOT and operated by the HSE in Dublin, Ireland, 
and secondly to estimate risk factors associated with 
HCV infection among this particular patient cohort. 
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2. Methods
2.1. Setting
The HSE is the national executive responsible 
for the provision of AOT in Ireland. Methadone treat-
ment services are provided via specialist addiction 
treatment centres, community-based clinics) and gen-
eral practitioners (GPs). This study was conducted 
in a satellite clinic in Dublin’s North Inner City. The 
clinic’s viral screening policy is to offer all patients 
a complete viral drug screen within a one month pe-
riod of starting AOT. This screen includes testing for 
Hepatitis A, B, and C and HIV infection. Each patient 
is reviewed annually to assess if further risk behav-
iour has occurred and is retested where appropriate. 
Testing for HCV antibodies (anti-HCV) is carried 
out using a third generation enzyme-linked Immuno-
absorbent Assay (ELISA). Alternatively, if a patient 
reports that a viral screen has been taken recently at 
another location, following the getting of the patients’ 
written consent the test results are verified in writing 
by the National Virus Reference Laboratory (NVRL). 
These results are kept in the patients’ clinical records. 
Ethical approval for the study was granted by the 
School of Health Sciences Ethics Committee, School 
of Medicine, Trinity College Dublin, Ireland.
2.2. Sample
The study sample (n=273) was the number of 
patients registered on the Central Treatment List (a 
national register for all patients in receipt of AOT) 
and attending the Thompson Centre for AOT on 31 
January 2015. A Patient Information Letter (PIL) was 
given to each patient. The letter explained the purpose 
of the study and the requirements for involvement. 
The gatekeeper explained the study in detail and an-
swered any questions or concerns which arose in this 
regard. Seven days after the date of distribution of the 
letter, author one (DK) met each patient at their next 
clinic appointment and a consent form was read to 
each patient. The patient then indicated, in writing, 
his/her consent or refusal to allow the researcher ac-
cess to their medical records for the purposes of the 
study. Out of 273 suitable patients, 45 were excluded 
for the reasons outlined in Figure 1, with 228 patients 
remaining. 
2.3. Data collection
The data was extracted from historical records 
obtained from the medical charts (written and com-
puterized) held on each patient at the study site. Prior 
to initiation onto AOT, the clinic nurse completes a 
standardised initial assessment and Health Research 
Board (HRB) form on each patent. These forms col-
lect a range of demographic and clinical details on 
each patient, including patient date of birth (DOB); 
sex; age of first drug use, type of first drug used, age 
of first injection, date of first episode of AOT, history 
of IDU and HCV status. The data submitter extracted 
all available data from completed written assessment 
and HRB forms. In instances where data was missing 
from the written records, the data controller reviewed 
electronic records and extracted the relevant missing 
Figure 1. Recruitment and exclusion of patients
6 refused 
1 deceased 
27 incarcerated / 
hospitalised 
transferred to 11 refused 
viral screens 
228 included 
273 patients suitable for inclusion 
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data and provided it to the data submitter. 
At the initial phase of data entry onto Excel, pa-
tients’ initials were used and only the data submitter 
had access to the records, which were held on a pass-
word protected computer at the study location. Once 
the data entry was complete, each patient’s record 
was anonymised by removing the patient’s initials 
and replacing them with a numerical identifier. An 
audit of the data set was conducted on patients with 
HCV antibody positive results in order to verify that 
the data submitter’s HCV status recording matched 
the HCV status on the patient’s records thus giving an 
accurate representation of HCV prevalence.
2.4. Data analysis
The statistical analysis was performed using the 
Statistical Package for Social Sciences (Version 21.0; 
SPSS UK Ltd; Chersey, UK). Data was assessed for 
normality by means of a Kolmogorov-Smirnov test 
and Q-Q plots, and the data was log-transformed for 
normalization purposes. Data are expressed as means 
and Standard Deviations (SD) and where appropriate, 
an independent sample T-test was applied to determine 
statistical significance (p≤0.05). Categorical variables 
were assessed by chi-square analysis. A multinomial 
logistic regression analysis was performed to deter-
mine the predictors of HCV positive results.
3. Results
3.1. Patient demographics and HCV infection
Of the 228 study participants, 168 (73.7%) were 
male and 60 (26.3%) were female. In total, 145 of 
the 228 patients tested positive for HCV antibodies 
giving an overall prevalence in this cohort of 63.6%. 
There was no significant difference between gender 
and HCV status. Approximately, 57 (25%) were aged 
between 21-34 years, termed 'younger adults' and 171 
(75%) were aged between 35 and 65 years, termed 
‘older adults’. The mean age of the study participants 
at cohort entry was 39.7 years (SD 8.0) with an age 
range of 21 to 65 years. Age was found to be statis-
tically significant in HCV status; patients who were 
infected with HCV were older than those who were 
uninfected (41.1 ± 7.5 years versus 37.5 ± 8.5 years; 
p = 0.001). The prevalence of a HCV positive result 
was significantly lower in younger adults compared 
to older adults (p=0.002).
3.2. Drug related risk factors
Analysis of the type of first drug used showed 
that the vast majority of the sample used canna-
bis (70%) followed by heroin (8.3%) and benzodi-
azepines (6.6%). The use of cannabis (p= 0.05) co-
Table 1. Demographic characteristics, drug use behaviour and HCV status of patients
  Total (n=228) HCV Antibody Negative(n=83)
HCV Antibody 
Positive(n=145) P-Value**
Age (yrs) * 39.7 ± 8.0 37.5 ± 8.5 41.1 ± 7.5 0.001
Female n (%) 60(26.3) 23(27.7) 37(25.5) 0.717
Age first drug use (yrs) * 15.4 ± 5.1 16.8 ± 6.9 14.6 ± 3.5 0.002
Type of first drug n (%)
Alcohol 7 (3.1) 3(3.6) 4(2.8) 0.719
Benzodiazepine Hypnotic 15(6.6) 2(2.4) 13(9) 0.055
Cannabis 150 (65.8) 63(75.9) 87(60) 0.015
Cocaine 1(0.4) 1(1.2) 1(0.4) 0.018
Ecstasy 3(1.3) 2(2.4) 1(0.7) 0.273
Hallucinogens-Lysergic 6(2.6) 1(1.2) 5(3.4) 0.309
Heroin 19(8.3) 2(2.4) 17(11.7) 0.014
Opioid tablet 2(0.9) 1(1.2) 1(0.7) 0.688
Opioids 12(5.3) 6(7.2) 6(4.1) 0.315
Solvents 3(1.3) 0 3(2.1) 0.187
Stimulants 8(3.5) 1(1.2) 7(4.8) 0.153
Benzodiazepine 2(0.9) 1(1.2) 1(0.7) 0.688
Age first IDU (yrs) * 21.7±7.2 26.5 ± 8.6 20.1 ± 6.0 <0.001
Age first AOT (yrs) * 24.9 ± 7.7 27.3 ± 8.2 23.5± 7.1 <0.001
Mean & SD=Standard Deviation; **P assessed by independent T-test or chi-squared analysis where applicable. P-value ≤ (0.05) 
set for levels of significance.
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caine (p=0.015) and heroin (p=0.014) as a first drug 
was significantly associated with HCV infection. 
Other substances such as the use of opioid tablets (p= 
0.315), stimulants (p=0.153), alcohol (p=0.719) and 
benzodiazepines (p=0.69) as a first time drugs used 
were not significantly associated with HCV infection. 
The patients infected with HCV were statistically 
significantly younger at first drug use (p=0.002), first 
IDU (p< 0.001) and first AOT (p<0.001). Table 1.
3.3. Multivariate analysis: All Cases
A multiple logistic regression analysis was con-
ducted on factors significantly associated with HCV 
status in the univariate analyses: age, age of first drug 
use, age of first IDU and age of first AOT. Analyses 
investigated the effects of patient age, sex, age of first 
drug use, age of first IDU and age of first AOT on a 
HCV positive result, in order to calculate increased or 
decreased risks of infection. Table 2. 
In the regression analysis of all cases using HCV 
negative as the reference category, with increasing 
age the odds of being in the HCV positive group in-
creased by 11.1%, while with each unit increase in 
age of first AOT, the odds of being in the HCV posi-
tive group decreased by 10.8%. Those with no history 
of IDU had decreased odds of being HCV positive 
by 91.1%. In a regression analysis of all cases IDU 
only using HCV negative as the reference category, 
with each unit increase in age, the odds of being in the 
HCV positive group increased by 14.8% while with 
each unit increase in age of first IDU, the odds of be-
ing in the HCV positive group decreased by 10.8%. 
Table 3. 
3.4. Multivariate analysis: Females
In a regression analysis of females only using 
HCV as the reference category, it was observed that 
with each unit increase in age of first AOT, the odds of 
being in the HCV positive group decreased by 12.6%. 
Females with no IDU had decreased odds of being 
HCV positive by 93.5%. (Table 4 and 5). 
3.5. Multivariate analysis: Males
In a regression analysis of males only using 
HCV negative as the reference, with increasing age, 
the odds of being in the HCV positive group increased 
by 13.6%, while with each unit increase in age of first 
time drug use, the odds of being in the HCV positive 
group decreased by 14.9%. With each unit increase in 
age of first AOT, the odds of being in the HCV posi-
tive group decreased by 10.9%. Patients with no IDU 
had decreased odds of being HCV positive by 91.1%. 
Males with no IDU had decreased odds of being HCV 
Table 2. All Cases
 Variable  Test  β-Value Odds ratio 95% Confidence Interval  p Value
Age (yrs) - + 0.105 1.111 1.051 – 1.175 <0.001
Age First time Drug use (yrs) - -0.077 0.926 0.850 – 1.009 0.079
Age First time AOT (yrs) - - 0.114 0.892 0.843 – 0.944 <0.001
Reference Category
Male Female + 0.233 1.262 0.571 – 2.792 0.565
IDU Yes IDU No - 2.491 0.089 0.040 – 0.198 <0.001
Reference category is HCV Negative (Multinomial logistic regression) 
Table 3. All cases IDU only
 Variable  Test
 
β-Value Odds ratio 95% Confidence Interval
 
P Value
Age (yrs) - + 0.138 1.148 1.071 – 1.231 <0.001
Age 1st Drug use (yrs) - -0.045 0.956 0.870 – 1.049 0.342
Age 1st AOT T (yrs) - - 0.062 0.940 0.870 – 1.016 0.121
Age 1st IDU (yrs) - - 0.114 0.892 0.040 – 0.198 0.008
Reference Category
Male Female + 0.463 1.589 0.575 – 4.392 0.372
Reference category is HCV Negative (Multinomial logistic regression)
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positive by 90.6%. In a regression analysis of males 
IV use only using HCV negative as the reference cat-
egory, with increasing age, the odds of being in the 
HCV positive group increased by 18.8%, while with 
each unit increase in age first IDU, the odds of being 
in the HCV positive group decreased by 13.0%. (Ta-
ble 6 and 7). 
4. Discussion
PWID constitute a high-risk and high-preva-
lence population for HCV infection [28, 41]. This 
Irish study presents prevalence data of HCV infec-
tion in a North Dublin clinic providing patients with 
AOT. The 3:1 male to female ratio is a consistent ratio 
for patients on AOT and in the general opioid using 
population. The prevalence rate of 63.6% among this 
cohort falls within the range reported in the available 
Irish literature [21, 33, 43, 45], in Europe [19] and the 
US [17, 39]. The systematic approach to viral screen-
ing and risk assessment with repeat testing at the cen-
tre enhances reliability of this estimate, along with 
the high follow-up rate (84%). We speculate given 
the high retention rate of AOT patients (>95%) in the 
Table 4. Females only
 Variable  Test  β-Value Odds ratio 95% Confidence Interval  P Value
Age (yrs) - + 0.045 1.046 0.931 – 1.174 0.448
Age 1st Drug use (yrs) - + 0.094 1.098 0.924 – 1.306 0.289
Age 1st AOT (yrs) - - 0.135 0.874 0.766 – 0.996 0.044
Reference Category
IDU Yes IV use No - 2.739 0.065 0.013 – 0.325 0.065
Reference category is Hep C Negative (Multinomial logistic regression)
Table 7. Males IDU only
 Variable Test  β-Value Odds ratio 95% Confidence Interval  P Value
Age (yrs) - + 0.172 1.188 1.088 – 1.297 <0.001
Age 1st Drug use (yrs) - - 0.137 0.872 0.731 – 1.041 0.129
Age 1st AOT (yrs) - - 0.081 0.922 0.842 – 1.009 0.078
Age 1st IDU (yrs) - - 0.139 0.870 0.784 – 0.966 0.009
Reference category is Hep C Negative (Multinomial logistic regression)
Table 5. Females IDU only
 Variable  Test  β-Value Odds ratio 95% Confidence Interval  P Value
Age (yrs) - + 0.041 1.041 0.893 – 1.214 0.604
Age 1st Drug use (yrs) - + 0.093 1.097 0.885 – 1.360 0.398
Age 1st AOT (yrs) - - 0.008 0.992 0.774 – 1.272 0.951
Age 1st IDU (yrs) - - 0.072 0.931 0.743 – 1.165 0.531
Reference category is Hep C Negative (Multinomial logistic regression
Table 6. Males only
 Variable  Test  β-Value Odds ratio 95% Confidence Interval  P Value
Age (yrs) - + 0.127 1.136 1.062 – 1.214 <0.001
Age 1st Drug use (yrs) - - 0.162 0.851 0.743 – 0.974 0.019
Age 1st AOT (yrs) - - 0.116 0.891 0.835 – 0.950 <0.001
Reference Category
IDU Yes IV use No - 2.362 0.094 0.035 – 0.251 <0.001
Reference category is Hep C Negative (Multinomial logistic regression)
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only a minority of participants visiting primary care. 
This study highlighted the need to intensify efforts to 
engage PWID with GPs, particularly in combination 
with harm reduction. AOT can underpin successful 
HCV prevention interventions by treating non injec-
tors, preventing their transitioning to injecting, and 
as a platform to engage HCV infected PWID in the 
HCV cascade of care continuum [41]. However, for 
patients attending AOT in primary care settings rou-
tine testing and vigilance is required. Revised interna-
tional recommendations for the management of HCV 
infection among PWID stipulate how high coverage 
of combined AOT and NSP programs can reduce 
HCV incidence, as well as AOT on own in reduc-
ing HCV transmissions and injecting risk behaviours 
[15]. Engaging opiate drug users in AOT at earlier 
stages in their drug using trajectories warrants con-
sideration in further planning for preventative HCV 
interventions in Ireland. Of interest was the finding 
that with each unit increase in age of first AOT, the 
odds of being in the HCV positive group decreased 
by 10.8% indicating that the younger the first of age 
of AOT the more likely the patient was to be HCV 
infected. This finding was unexpected and was the 
reverse to what might have been predicted, and may 
reflect earlier starting age for drug use and/or IDU, 
and increased severity of drug use amongst these 
younger AOT patients. Further research on younger 
drug users, and on patients infected with HCV with 
no history of injecting is warranted to explore specific 
risk factors, and informed targeted HCV prevention 
strategies. Additionally, data around co-infection in 
Ireland needs surveillance.
Limitations
Limitations of the study centre on the conveni-
ence nature of the sample and the availability of med-
ical records. It was also beyond the scope of the cur-
rent study to examine the relationship between HCV 
infection and other factors such as injecting practices 
(frequency of injecting and engaging in risk behav-
iours such as back-loading and sharing needles, loca-
tion of injecting) and socio-demographic characteris-
tics (education and employment history, time spent in 
prison etc.).
5. Conclusions
Irish studies have indicated success with opt-
out blood borne viral screening at different clinical 
settings [40]. However, marginalised subgroups of 
clinic, and the mix of patients attending, that the prev-
alence rate is generalizable to the wider problematic 
drug using population in the Dublin area. The high 
prevalence rate of HCV infection is a cause for con-
cern and underscores the need for renewed efforts in 
primary prevention (including vaccine development), 
as well as new approaches to secondary and tertiary 
prevention in order to reduce the burden of chronic 
liver disease and to improve survival for these drug 
users having signs of liver disease. 
This study has identified particular risk factors 
for HCV infection which can inform and target pre-
vention strategies. Risks identified are similar to other 
studies by identifying IDU as risk factor and age, with 
HCV prevalence increasing particularly among those 
reporting injecting behaviours. No gender difference 
was reported. Of note was that patients with no inject-
ing history had decreased odds of being HCV positive 
by 91.1%. Our study supports the need for enhanced 
focus on interventions reaching out to non-injectors 
to deter injecting, interventions likely to reduce in-
jecting or stimulate reverse route transitioning, as 
well as promoting safe injecting tactics [34]. Other 
indicators centred on age of first-time drug use and 
first injecting drug use, and types of first drugs used. 
Age of first IDU in this study was found to be associ-
ated with an increased risk of HCV infection. Larney 
et al. [27] have underscored the need to gain a great-
er understanding of those who have ‘ever’ injected 
drugs, including those who did so for a short duration 
or infrequently, in order to understand and character-
ize HCV infection among PWID. The transmission 
of HCV is complex among PWID, with many trans-
mission events occurring between infected older and 
younger injectors, and phylogenetic clustering asso-
ciated with younger age and HIV [24]. Of note is that 
some PWID despite long injection histories remained 
uninfected [11]. 
Barriers to effective HCV management amongst 
Irish injecting drug users centre on negative experi-
ences at diagnosis, investigations and treatment and 
are similar to structural barriers reported elsewhere 
[8, 53]. The report by Long in 2006 [33] on blood 
borne viral infections among PWID in Ireland indi-
cated a decentralised approach to HCV treatment with 
the initial assessment being done in general practice 
and treatment provided at local drug treatment cen-
tre achieved higher uptake and compliance rates than 
the hospital based centralised approach. Artenie et 
al. [2] have reported that for PWID attending harm 
reduction services, visiting a primary care provider 
was related to lower risk of HCV infection, despite 
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PWID are less likely to access health care due to 
stigma, discrimination, and health care professional 
misunderstanding of their needs and their lifestyles. 
A comprehensive and scaled up HCV treatment and 
prevention approach to address HCV transmission 
rates among PWID situated in medical infrastruc-
tures designed for drug user health (e.g. community 
health centres, AOT clinics, primary care), with spe-
cialist support, elements of harm reduction and access 
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